Barchart6d agoneutral
Why DataMEDS’ Acquisition Does Not Seem to Be Very Bullish for MEDS Stock at This PointThe low purchase price of Helomics and low revenue suggest that the acquisition is not that promising for DataMEDS AI.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
142last 24h
874last 7d
146● bullish (7d)
99● bearish (7d)
214publishers